Literature DB >> 10782780

Structural changes of the substantia nigra in Parkinson's disease as revealed by MR imaging.

M Hutchinson1, U Raff.   

Abstract

BACKGROUND AND
PURPOSE: The possibility of using MR imaging as a sensitive marker of the structural changes in Parkinson's disease has been a long-sought goal. We describe a new method for imaging and quantifying the morphologic changes of the substantia nigra in Parkinson's disease and compare radiologic findings with clinical evaluation.
METHODS: Using a combination of two MR imaging inversion-recovery pulse sequences, the substantia nigra was imaged in six patients with Parkinson's disease and six age-related control participants. A radiologic index was defined and used to quantify the signal changes that were observed in the patients. The radiologic index was compared with clinical scores obtained from the Unified Parkinson's Disease Rating Scale.
RESULTS: The images showed loss of signal in a lateral-to-medial gradient in cases of Parkinson's disease, corresponding to the known neuropathologic pattern of degeneration. The radiologic index was highly correlated with the Unified Parkinson's Disease Rating Scale score, and there was no overlap in radiologic indices between the patient and the control groups (P < .00005).
CONCLUSION: This study suggests that MR imaging is sensitive to structural changes in even the earliest cases of Parkinson's disease, thereby indicating the potential for detecting presymptomatic disease. Furthermore, a radiologic measure has been defined that correlates with the conventional clinical measure of disease severity. Therefore, MR imaging could prove to be a sensitive biological marker for objective staging of the disease.

Entities:  

Mesh:

Year:  2000        PMID: 10782780      PMCID: PMC7976637     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  17 in total

Review 1.  Restorative gene therapy approaches to Parkinson's disease.

Authors:  A Freese
Journal:  Med Clin North Am       Date:  1999-03       Impact factor: 5.456

2.  Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease.

Authors:  J P Seibyl; K L Marek; D Quinlan; K Sheff; S Zoghbi; Y Zea-Ponce; R M Baldwin; B Fussell; E O Smith; D S Charney; C van Dyck
Journal:  Ann Neurol       Date:  1995-10       Impact factor: 10.422

Review 3.  The detection of preclinical Parkinson's disease: what is the role of positron emission tomography?

Authors:  G V Sawle
Journal:  Mov Disord       Date:  1993-07       Impact factor: 10.338

Review 4.  Motor disturbance and brain functional imaging in Parkinson's disease.

Authors:  D J Brooks
Journal:  Eur Neurol       Date:  1997       Impact factor: 1.710

5.  Evaluation of [123I] beta-CIT binding with SPECT in controls, early and late Parkinson's disease.

Authors:  R J Vermeulen; E C Wolters; G Tissingh; J Booij; A G Janssen; J Habraken; E Sokole-Busemann; J C Stoof; E A Van Royen
Journal:  Nucl Med Biol       Date:  1995-11       Impact factor: 2.408

6.  Ageing and Parkinson's disease: substantia nigra regional selectivity.

Authors:  J M Fearnley; A J Lees
Journal:  Brain       Date:  1991-10       Impact factor: 13.501

Review 7.  The use of PET in Parkinson's disease.

Authors:  H Shinotoh; D B Calne
Journal:  Brain Cogn       Date:  1995-08       Impact factor: 2.310

Review 8.  Adenovirus in the brain: recent advances of gene therapy for neurodegenerative diseases.

Authors:  M Barkats; A Bilang-Bleuel; M H Buc-Caron; M N Castel-Barthe; O Corti; F Finiels; P Horellou; F Revah; O Sabate; J Mallet
Journal:  Prog Neurobiol       Date:  1998-07       Impact factor: 11.685

9.  Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.

Authors:  J P Seibyl; K Marek; K Sheff; S Zoghbi; R M Baldwin; D S Charney; C H van Dyck; R B Innis
Journal:  J Nucl Med       Date:  1998-09       Impact factor: 10.057

10.  Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease.

Authors:  J M Gorell; R J Ordidge; G G Brown; J C Deniau; N M Buderer; J A Helpern
Journal:  Neurology       Date:  1995-06       Impact factor: 9.910

View more
  21 in total

Review 1.  Positron emission tomography and single-photon emission computed tomography in central nervous system drug development.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2005-04

2.  Investigation of morphometric variability of subthalamic nucleus, red nucleus, and substantia nigra in advanced Parkinson's disease patients using automatic segmentation and PCA-based analysis.

Authors:  Yiming Xiao; Pierre Jannin; Tiziano D'Albis; Nicolas Guizard; Claire Haegelen; Florent Lalys; Marc Vérin; D Louis Collins
Journal:  Hum Brain Mapp       Date:  2014-02-19       Impact factor: 5.038

Review 3.  Neuroimaging in Parkinson's disease.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2004-04

4.  Striatal volume differences between non-human and human primates.

Authors:  Dali Yin; Francisco E Valles; Massimo S Fiandaca; John Forsayeth; Paul Larson; Phillip Starr; Krystof S Bankiewicz
Journal:  J Neurosci Methods       Date:  2008-09-02       Impact factor: 2.390

5.  Multi-contrast unbiased MRI atlas of a Parkinson's disease population.

Authors:  Yiming Xiao; Vladimir Fonov; Silvain Bériault; Fahd Al Subaie; M Mallar Chakravarty; Abbas F Sadikot; G Bruce Pike; D Louis Collins
Journal:  Int J Comput Assist Radiol Surg       Date:  2014-05-20       Impact factor: 2.924

6.  Evaluation of treatment effects in Alzheimer's and other neurodegenerative diseases by MRI and MRS.

Authors:  S G Mueller; N Schuff; M W Weiner
Journal:  NMR Biomed       Date:  2006-10       Impact factor: 4.044

Review 7.  Unbiased approaches to biomarker discovery in neurodegenerative diseases.

Authors:  Alice S Chen-Plotkin
Journal:  Neuron       Date:  2014-11-05       Impact factor: 17.173

8.  Magnetic transfer contrast accurately localizes substantia nigra confirmed by histology.

Authors:  Mark S Bolding; Meredith A Reid; Kathy B Avsar; Rosalinda C Roberts; Paul D Gamlin; Timothy J Gawne; David M White; Jan A den Hollander; Adrienne C Lahti
Journal:  Biol Psychiatry       Date:  2012-09-12       Impact factor: 13.382

Review 9.  Disturbance of iron metabolism as a contributing factor to SN hyperechogenicity in Parkinson's disease: implications for idiopathic and monogenetic forms.

Authors:  Daniela Berg
Journal:  Neurochem Res       Date:  2007-04-28       Impact factor: 3.996

10.  Case control study of diffusion tensor imaging in Parkinson's disease.

Authors:  L-L Chan; H Rumpel; K Yap; E Lee; H-V Loo; G-L Ho; S Fook-Chong; Y Yuen; E-K Tan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-07-05       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.